SubsidieMeestersFluid Biomarkers for Neurodegenerative Dementias
The project aims to develop high-throughput biomarker tools for Alzheimer's and neurodegenerative diseases, enabling comprehensive analysis for diagnostics, drug discovery, and personalized medicine.
Projectdetails
Introduction
Critical to our understanding of Alzheimer’s disease (AD) and other neurodegenerative dementias (NDDs), as well as to finding disease-modifying therapies, is the development of biomarkers for the underlying disease processes.
Biomarker Development
To facilitate improved diagnostics and drug discovery, we have developed methods to measure markers of:
- Amyloid and tau pathology
- Central and peripheral nervous system injury
- Astrocytic and microglial activation
- Neuroinflammation
Our most exciting advancement in this field so far is the development of phosphorylated tau assays sensitive enough to measure this protein in plasma to detect AD pathology in the brain and to allow for disease stratification and monitoring based on AD pathology.
Proposed Research
I now propose to develop new high-throughput biomarker tools that will enable the analysis of large cohort studies combining:
- Clinical data
- Imaging data
- Genetic data
- Biomarker data
This comprehensive approach will provide truly comprehensive molecular disease phenotypes that will inform interventions, drug discovery, translational research, clinical trial stratification, detection of risk and resilience factors (lifestyle-related, as well as genetic), and ultimately drive the quest towards clinically accessible personalized medicine in the NDD field.
Focus Areas
A large part of the research efforts will be focused on discovering new biomarkers for:
- TDP-43 and α-synuclein pathologies
- Non-AD tau pathology
- Lysosomal and synaptic dysfunction
This will be achieved through general and targeted proteomics on CSF samples, and by employing a novel cell type-biased tandem mass tag proteomics workflow to discover biomarkers related to neuronal, astrocytic, and microglial cells, and their different activation states.
Biomarker Validation
Promising CSF biomarkers will be examined in blood. Biomarker candidates that are measurable in this matrix and correlate with CSF will be developed into sensitive and specific blood tests using cutting-edge technology, as we have previously done for:
- Aβ40
- Aβ42
- T-tau
- P-tau
- NfL
- GFAp
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.422.973 |
| Totale projectbegroting | € 2.422.973 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 31-8-2027 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- GOETEBORGS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s diseaseADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Window to the brain: a game changer in the discovery of human neuronal circuitry, cellular heterogenicity and biomarker profile indicative of early Alzheimer's disease -related pathologyThe project aims to investigate how specific microglial subpopulations impair neuronal functions in early Alzheimer's pathology using unique human brain samples and advanced techniques to identify novel biomarkers. | ERC Consolid... | € 1.998.389 | 2022 | Details |
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors. | ERC Consolid... | € 2.999.934 | 2025 | Details |
Global Amyloid Mapping: Solving Amyloid Nucleation by Deep MutagenesisThis project aims to map mutations affecting amyloid nucleation, model transition states, and identify stress-responsive sequences to enhance understanding and treatment of amyloid-related diseases. | ERC Consolid... | € 1.999.008 | 2024 | Details |
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncologyNanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes. | ERC Starting... | € 1.494.954 | 2025 | Details |
Novel biomarkers for improving diagnostics, prognostics, and treatments of Alzheimer’s disease
ADVANCE-AD aims to enhance Alzheimer's diagnostics and treatment by developing cost-effective blood-based biomarkers and algorithms for early detection and intervention in pre-symptomatic patients.
Window to the brain: a game changer in the discovery of human neuronal circuitry, cellular heterogenicity and biomarker profile indicative of early Alzheimer's disease -related pathology
The project aims to investigate how specific microglial subpopulations impair neuronal functions in early Alzheimer's pathology using unique human brain samples and advanced techniques to identify novel biomarkers.
Deciphering Alzheimer’s disease molecular subtypes to advance treatment development.
This project aims to identify Alzheimer's disease subtypes through CSF proteomics to develop tailored treatments and theragnostic tools linked to cognitive decline and genetic factors.
Global Amyloid Mapping: Solving Amyloid Nucleation by Deep Mutagenesis
This project aims to map mutations affecting amyloid nucleation, model transition states, and identify stress-responsive sequences to enhance understanding and treatment of amyloid-related diseases.
Nanotechnology-enabled deep profiling of the blood and brain proteome at the intersection of neurodegeneration and neurooncology
NanoNeuroOmics aims to discover early blood biomarkers for Alzheimer's and Glioblastoma using nanotechnology and proteomics to bridge the gap between brain and blood molecular changes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug developmentATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development
ATI's AT-001 aims to stop and revert dementia by preventing protein aggregation, with promising Phase IIa results leading to upcoming registration trials and POC studies for commercialization.